supplementary materials.docx (1.48 MB)

Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA: Supplementary materials

dataset

posted on 2022-11-04, 11:03 authored by Darshan Mehta, Inyoung Lee, Hangcheng Liu, Mitchell DeKoven, Brian Wensel, G. Rhys Williams

Aim: To compare all-cause and epilepsy-specific pharmacy and total costs associated with initiation of

eslicarbazepine acetate (ESL) or brivaracetam (BRV) among patients with focal seizures in long-term care

(LTC) in theUS. Methods: This retrospective analysis used data from IQVIA’s New DataWarehouse. Results:

298 patients initiated ESL and 282 patients initiated BRV. Initiation of ESL versus BRV was associated with

33.3% lower all-cause pharmacy costs, 34.4% lower epilepsy-specific pharmacy costs, 21.3% lower all-cause

total costs and 30.9% lower epilepsy-specific total costs (all p < 0.0001). Conclusion: Among patients with

focal seizures in LTC in the US, initiation of ESL versus BRV was associated with significant reductions in

all-cause and epilepsy-specific pharmacy and total costs compared with initiation of BRV.

Funding